Bioxcel Therapeutics Stock Today

BTAI Stock  USD 2.88  0.02  0.70%   

Performance

3 of 100

 
Low
 
High
Insignificant

Odds Of Distress

Over 81

 
100  
 
Zero
Very High
BioXcel Therapeutics is trading at 2.88 as of the 28th of March 2024. This is a 0.70 percent up since the beginning of the trading day. The stock's open price was 2.86. BioXcel Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for BioXcel Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of April 2022 and ending today, the 28th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
8th of March 2018
Category
Healthcare
Classification
Health Care
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut. The company has 30.58 M outstanding shares of which 3.14 M shares are currently shorted by private and institutional investors with about 1.23 trading days to cover. More on BioXcel Therapeutics

Moving against BioXcel Stock

  0.43YS YS Biopharma Report 22nd of April 2024 PairCorr

BioXcel Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. BioXcel Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding BioXcel Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEOVimal Mehta
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering BioXcel Therapeutics report their recommendations after researching BioXcel Therapeutics' financial statements, talking to executives and customers, or listening in on BioXcel Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering BioXcel Therapeutics. The BioXcel consensus assessment is calculated by taking the average forecast from all of the analysts covering BioXcel Therapeutics.
Financial Strength
Based on the key indicators related to BioXcel Therapeutics' liquidity, profitability, solvency, and operating efficiency, BioXcel Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter. Financial strength of BioXcel Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.01970.0187
Sufficiently Up
Slightly volatile
Total Current Liabilities28.6 M27.3 M
Sufficiently Up
Slightly volatile
Total Assets100.3 M73.7 M
Significantly Up
Slightly volatile
Total Current Assets98.2 M72.1 M
Significantly Up
Slightly volatile
BioXcel Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to BioXcel Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand BioXcel Therapeutics' financial leverage. It provides some insight into what part of BioXcel Therapeutics' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on BioXcel Therapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how BioXcel Therapeutics deploys its capital and how much of that capital is borrowed.
Liquidity
BioXcel Therapeutics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 101.38 M in liabilities with Debt to Equity (D/E) ratio of 0.38, which is about average as compared to similar companies. BioXcel Therapeutics has a current ratio of 12.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist BioXcel Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, BioXcel Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioXcel Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioXcel to invest in growth at high rates of return. When we think about BioXcel Therapeutics' use of debt, we should always consider it together with cash and equity.

Total Cash From Operating Activities

(147.26 Million)
BioXcel Therapeutics (BTAI) is traded on NASDAQ Exchange in USA. It is located in 555 Long Wharf Drive, New Haven, CT, United States, 06511 and employs 74 people. BioXcel Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 87.45 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BioXcel Therapeutics's market, we take the total number of its shares issued and multiply it by BioXcel Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. BioXcel Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 30.58 M outstanding shares of which 3.14 M shares are currently shorted by private and institutional investors with about 1.23 trading days to cover. BioXcel Therapeutics currently holds about 233.45 M in cash with (155.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.33, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check BioXcel Therapeutics Probability Of Bankruptcy
Ownership Allocation
BioXcel Therapeutics retains a total of 30.58 Million outstanding shares. BioXcel Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check BioXcel Ownership Details

BioXcel Stock Price Odds Analysis

Coming from a normal probability distribution, the odds of BioXcel Therapeutics jumping above the current price in 90 days from now is about 60.65%. The BioXcel Therapeutics probability density function shows the probability of BioXcel Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.1413 suggesting BioXcel Therapeutics market returns are responsive to returns on the market. As the market goes up or down, BioXcel Therapeutics is expected to follow. Additionally, bioXcel Therapeutics has an alpha of 0.223, implying that it can generate a 0.22 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 2.88HorizonTargetOdds Above 2.88
39.23%90 days
 2.88 
60.65%
Based on a normal probability distribution, the odds of BioXcel Therapeutics to move above the current price in 90 days from now is about 60.65 (This BioXcel Therapeutics probability density function shows the probability of BioXcel Stock to fall within a particular range of prices over 90 days) .

BioXcel Stock Institutional Holders

Institutional Holdings refers to the ownership stake in BioXcel Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of BioXcel Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing BioXcel Therapeutics' value.
InstituionRecorded OnShares
Jane Street Group, Llc2023-09-30
141.7 K
Bank Of New York Mellon Corp2023-12-31
126.5 K
Arete Wealth Advisors, Llc2023-12-31
109.2 K
Bank Of America Corp2023-12-31
104.3 K
Millennium Management Llc2023-12-31
88 K
Pennant Investors Lp2023-12-31
83.9 K
Wells Fargo & Co2023-12-31
77.8 K
Virtu Financial Llc2023-12-31
59.5 K
Squarepoint Ops Llc2023-12-31
57.1 K
Fmr Inc2023-12-31
2.5 M
Blackrock Inc2023-12-31
1.4 M
View BioXcel Therapeutics Diagnostics

BioXcel Therapeutics Historical Income Statement

BioXcel Therapeutics Income Statement is one of the three primary financial statements used for reporting BioXcel's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of BioXcel Therapeutics revenue and expense. BioXcel Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
As of now, BioXcel Therapeutics' Other Operating Expenses is increasing as compared to previous years. The BioXcel Therapeutics' current Cost Of Revenue is estimated to increase to about 1.7 M, while Operating Income is forecasted to increase to (158 M). View More Fundamentals

BioXcel Stock Against Markets

Picking the right benchmark for BioXcel Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in BioXcel Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for BioXcel Therapeutics is critical whether you are bullish or bearish towards BioXcel Therapeutics at a given time. Please also check how BioXcel Therapeutics' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in BioXcel Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Idea Breakdown Now

   

Idea Breakdown

Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
All  Next Launch Module

BioXcel Therapeutics Corporate Management

Elected by the shareholders, the BioXcel Therapeutics' board of directors comprises two types of representatives: BioXcel Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioXcel. The board's role is to monitor BioXcel Therapeutics' management team and ensure that shareholders' interests are well served. BioXcel Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioXcel Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Vincent ONeillChief Medical OfficerProfile
Frank YoccaChief Scientific OfficerProfile
Mary ColemanVP RelationsProfile
Javier RodriguezChief VPProfile

How to buy BioXcel Stock?

Before investing in BioXcel Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in BioXcel Therapeutics. To buy BioXcel Therapeutics stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of BioXcel Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase BioXcel Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located BioXcel Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased BioXcel Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as BioXcel Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.

Already Invested in BioXcel Therapeutics?

The danger of trading BioXcel Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of BioXcel Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than BioXcel Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile BioXcel Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether BioXcel Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioXcel Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioxcel Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioxcel Therapeutics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioXcel Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
For more detail on how to invest in BioXcel Stock please use our How to Invest in BioXcel Therapeutics guide.
Note that the BioXcel Therapeutics information on this page should be used as a complementary analysis to other BioXcel Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for BioXcel Stock analysis

When running BioXcel Therapeutics' price analysis, check to measure BioXcel Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioXcel Therapeutics is operating at the current time. Most of BioXcel Therapeutics' value examination focuses on studying past and present price action to predict the probability of BioXcel Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioXcel Therapeutics' price. Additionally, you may evaluate how the addition of BioXcel Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Transaction History
View history of all your transactions and understand their impact on performance
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Is BioXcel Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioXcel Therapeutics. If investors know BioXcel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioXcel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.15)
Revenue Per Share
0.047
Quarterly Revenue Growth
0.58
Return On Assets
(0.75)
Return On Equity
(17.67)
The market value of BioXcel Therapeutics is measured differently than its book value, which is the value of BioXcel that is recorded on the company's balance sheet. Investors also form their own opinion of BioXcel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is BioXcel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioXcel Therapeutics' market value can be influenced by many factors that don't directly affect BioXcel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioXcel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioXcel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioXcel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.